Login
$BNTC
$8.54 -$0.50 (5.53%) Live

$BNTC 8-K SEC Filings

Filed On Filing
13 Nov 2026 8-K: Results of Operations and Financial Condition; Amendments to Articles/Bylaws; Change in Fiscal Year

Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGC...

28 Oct 2026 8-K: Regulation FD Disclosure

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

05 Oct 2026 8-K: Regulation FD Disclosure

The BB-301 pivotal trial remains on track to begin in mid-2027

30 Sep 2026 8-K: Changes in Registrant's Certifying Accountant

As previously disclosed on a Current Report on Form 8-K with the Securities and Exchange Commission that Benitec Biopharma Inc. (the “Company”) filed on September 24, 2026, the Company reported the approval of the engagement of Ernst & Y...

24 Sep 2026 8-K: Changes in Registrant's Certifying Accountant

We are the former independent registered public accounting firm for Benitec Biopharma Inc. (the “Company”). We have read the Company’s disclosure set forth in Item 4.01 “Changes in Registrant’s Certifying Accountant” of the Company’s Cur...

14 Sep 2026 8-K: Results of Operations and Financial Condition

All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated

29 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

On May 22, 2026, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed David Friedman to serve as a director of the Board, effective as of such date. Mr. Friedman was appointed as a Class III member of ...

14 May 2026 8-K: Results of Operations and Financial Condition

Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further i...

12 Feb 2026 8-K: Results of Operations and Financial Condition

-The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint de...

02 Dec 2025 8-K: Submission of Matters to a Vote of Security Holders

On December 1, 2025, Benitec Biopharma Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). The 2025 Annual Meeting was held virtually. A total of 22,327,761 shares of the Company’s common stock ...

14 Nov 2025 8-K: Results of Operations and Financial Condition

-Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301-

07 Nov 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Benitec Biopharma Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC (“Leerink Partners”), TD Securities (USA) LLC (“TD Cowen”), Evercore Group L.L.C. (“Evercore”), and each of the other Underw...

03 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more

Positive Clinical Data Supporting Advancement of BB-301 in OPMD WEBCAST: November 3, 2025 ©2025 Benitec Biopharma. All rights reserved. OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) A Debilitating, Progressive Disease With No Approved Therap...

22 Sep 2025 8-K: Results of Operations and Financial Condition

Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

12 Sep 2025 8-K: Non-Reliance on Previously Issued Financial Statements

In connection with the preparation of Benitec Biopharma Inc.’s (“Benitec,” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the “2025 Form 10-K”), the Company determined that in prior periods it had n...

09 Jul 2025 8-K: Regulation FD Disclosure

-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)-

14 May 2025 8-K: Results of Operations and Financial Condition

HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “S...

28 Mar 2025 8-K: Other Events

As previously announced, on March 25, 2025, Benitec Biopharma Inc., a Delaware corporation (the “Company”) entered into (A) an Underwriting Agreement with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the severa...

27 Mar 2025 8-K: Entry into a Material Definitive Agreement

This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 26, 2025, by and among Benitec Biopharma Inc., a Delaware corporation (the “Company”), Averill Master Fund, Ltd. (“Averill”) and Averill Madison M...

26 Mar 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Pre-Funded Warrants to Purchase up to 300,000 Shares of Common Stock

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support